Parvovirus B19 infection in the first trimester of pregnancy and risk of fetal loss: A population-based case-control study

American Journal of Epidemiology

Volumn 176, Issue 9, 2012, Pages 803-807

  Lassen, Jonathan ^a   Jensen, Anne K V ^a   Bager, Peter ^a   Pedersen, Carsten B ^a   Panum, Inge ^a   Norgaard Pedersen, Bent ^a   Aaby, Peter ^a   Wohlfahrt, Jan ^a   Melbye, Mads ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

communicable diseases; fetal loss; parvovirus B19, human; pregnancy complications

Indexed keywords

IMMUNOGLOBULIN M;

EPIDEMIC; HEALTH RISK; INFECTIOUS DISEASE; INFECTIVITY; PREGNANCY; RISK FACTOR; SERUM; SYPHILIS; VIRUS;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CAUSAL ATTRIBUTION; CONTROLLED STUDY; DENMARK; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; HUMAN PARVOVIRUS B19; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PARVOVIRUS INFECTION; POPULATION BASED CASE CONTROL STUDY; RISK FACTOR;

CASE-CONTROL STUDIES; DENMARK; FEMALE; FETAL DEATH; GESTATIONAL AGE; HUMANS; IMMUNOGLOBULIN M; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY TRIMESTER, FIRST; RISK FACTORS;

DENMARK;

PARVOVIRUS;

EID: 84868011292     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws177     Document Type: Article

References (25)

1. Anand A, Gray ES, Brown T, et al. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med. 1987;316(4):183-186.
2. Brown T, Anand A, Ritchie LD, et al. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet. 1984; 2(8410):1033-1034.
3. Brandenburg H, Los FJ, Cohen-Overbeek TE. A case of early intrauterine parvovirus B19 infection. Prenat Diagn. 1996; 16(1):75-77.
4. von Kaisenberg CS, Bender G, Scheewe J, et al. A case of fetal parvovirus B19 myocarditis, terminal cardiac heart failure, and perinatal heart transplantation. Fetal Diagn Ther. 2001;16(6):427-432.
5. Fairley CK, Smoleniec JS, Caul OE, et al. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet. 1995; 346(8986):1335-1337.
6. Rodis JF, Borgida AF, Wilson M, et al. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol. 1998;179(4):985-988.
7. Jellesen R, Strandberg-Larsen K, Jørgensen T, et al. Maternal use of oral contraceptives and risk of fetal death. Paediatr Perinat Epidemiol. 2008;22(4):334-340.
8. Valeur-Jensen AK, Pedersen CB, Westergaard T, et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA. 1999;281(12):1099-1105.
9. Jensen IP, Thorsen P, Jeune B, et al. An epidemic of parvovirus B19 in a population of 3,596 pregnant women: a study of sociodemographic and medical risk factors. BJOG. 2000;107(5):637-643.
10. Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease. BMJ. 1990;300(6733):1166-1170.
11. Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263-268.
12. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull. 1998;45(3):320-323.
13. Goldenberg RL, Kirby R, Culhane JF. Stillbirth: a review. J Matern Fetal Neonatal Med. 2004;16(2):79-94.
14. Enders M, Weidner A, Zoellner I, et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn. 2004;24(7):513-518.
15. Lohse SR, Farkas DK, Lohse N, et al. Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients. Clin Epidemiol. 2010;2:247-250.
16. Pedersen CB, Gøtzsche H, Møller JO, et al. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53(4):441-449.
17. Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. BMJ. 2000;320(7251):1708-1712.
18. Tolfvenstam T, Broliden K. Parvovirus B19 infection. Semin Fetal Neonatal Med. 2009;14(4):218-221.
19. Chisaka H, Ito K, Niikura H, et al. Clinical manifestations and outcomes of parvovirus B19 infection during pregnancy in Japan. Tohoku J Exp Med. 2006;209(4):277-283.
20. Gratacós E, Torres PJ, Vidal J, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis. 1995;171(5): 1360-1363.
21. Bruu AL, Nordbø SA. Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B 19. J Clin Microbiol. 1995;33(5):1363-1365.
22. Cohen BJ, Bates CM. Evaluation of 4 commercial test kits for parvovirus B 19-specific IgM. J Virol Methods. 1995; 55(1):11-25.
23. Harger JH, Adler SP, Koch WC, et al. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol. 1998;91(3):413-420.
24. Sarfraz AA, Samuelsen SO, Bruu AL, et al. Maternal human parvovirus B19 infection and the risk of fetal death and low birthweight: a case-control study within 35 940 pregnant women. BJOG. 2009;116(11):1492-1498.
25. Miller E, Fairley CK, Cohen BJ, et al. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol. 1998;105(2):174-178.